On May 8, 2023, Shanghai UniXell Biotechnology Co., Ltd. (hereinafter referred to as "UniXell ") announced that Ms. Emily Chen was appointed as the company's chief operating officer (COO). Ms. Emily Chen will lead the overall operation of the company
The autologous stem cell therapy project for Parkinson's disease launched this time will carry out a series of scientific research-clinical cooperation in strict compliance, including the establishment of iPSC libraries. It is reported that after the
On March 14, 2022, Shanghai UniXell Biotechnology Co., Ltd. (hereinafter referred to as "UniXell "), a leading company dedicated to the development of pluripotent stem cell drugs, announced the completion of nearly 200 million yuan in financing. This
On May 8, 2023, Shanghai UniXell Biotechnology Co., Ltd. (hereinafter referred to as "UniXell ") announced that Ms. Emily Chen was appointed as the company's chief operating officer (COO). Ms. Emily Chen will lead the overall operation of the company
The autologous stem cell therapy project for Parkinson's disease launched this time will carry out a series of scientific research-clinical cooperation in strict compliance, including the establishment of iPSC libraries. It is reported that after the
On March 14, 2022, Shanghai UniXell Biotechnology Co., Ltd. (hereinafter referred to as "UniXell "), a leading company dedicated to the development of pluripotent stem cell drugs, announced the completion of nearly 200 million yuan in financing. This
Recently, Shanghai UniXell Biotechnology Co., LTD. (UniXell), a leader in the field of pluripotent stem cell drug development, announced the completion of tens of millions of yuan angel round financing. This round of financing was led by Taifu Capita
